These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 19771321

  • 1. Neuropeptides: relevance in treatment of depression and anxiety disorders.
    Madaan V, Wilson DR.
    Drug News Perspect; 2009; 22(6):319-24. PubMed ID: 19771321
    [Abstract] [Full Text] [Related]

  • 2. Central CRH system in depression and anxiety--evidence from clinical studies with CRH1 receptor antagonists.
    Holsboer F, Ising M.
    Eur J Pharmacol; 2008 Apr 07; 583(2-3):350-7. PubMed ID: 18272149
    [Abstract] [Full Text] [Related]

  • 3. Mixed depression and anxiety: serotonin1A receptors as a common pharmacologic link.
    Stahl SM.
    J Clin Psychiatry; 1997 Apr 07; 58 Suppl 8():20-6. PubMed ID: 9236732
    [Abstract] [Full Text] [Related]

  • 4. Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders.
    Holmes A, Heilig M, Rupniak NM, Steckler T, Griebel G.
    Trends Pharmacol Sci; 2003 Nov 07; 24(11):580-8. PubMed ID: 14607081
    [Abstract] [Full Text] [Related]

  • 5. Galanin, galanin receptor subtypes and depression-like behaviour.
    Kuteeva E, Hökfelt T, Wardi T, Ogren SO.
    Cell Mol Life Sci; 2008 Jun 07; 65(12):1854-63. PubMed ID: 18500640
    [Abstract] [Full Text] [Related]

  • 6. The neurobiological basis of mixed depression-anxiety states.
    Gulley LR, Nemeroff CB.
    J Clin Psychiatry; 1993 Jan 07; 54 Suppl():16-9. PubMed ID: 8093884
    [Abstract] [Full Text] [Related]

  • 7. Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
    Keck ME.
    Amino Acids; 2006 Oct 07; 31(3):241-50. PubMed ID: 16733617
    [Abstract] [Full Text] [Related]

  • 8. Recent advances in the neurobiology of anxiety disorders: implications for novel therapeutics.
    Mathew SJ, Price RB, Charney DS.
    Am J Med Genet C Semin Med Genet; 2008 May 15; 148C(2):89-98. PubMed ID: 18412102
    [Abstract] [Full Text] [Related]

  • 9. The role of pharmacogenetics in the treatment of depression and anxiety disorders.
    Schosser A, Kasper S.
    Int Clin Psychopharmacol; 2009 Nov 15; 24(6):277-88. PubMed ID: 19738481
    [Abstract] [Full Text] [Related]

  • 10. Behavioral effects of neuropeptides in rodent models of depression and anxiety.
    Rotzinger S, Lovejoy DA, Tan LA.
    Peptides; 2010 Apr 15; 31(4):736-56. PubMed ID: 20026211
    [Abstract] [Full Text] [Related]

  • 11. Non-monoaminergic targets for the development of antidepressants: focus on neuropeptides.
    Catena-Dell'Osso M, Fagiolini A, Marazziti D, Baroni S, Bellantuono C.
    Mini Rev Med Chem; 2013 Jan 15; 13(1):2-10. PubMed ID: 22876945
    [Abstract] [Full Text] [Related]

  • 12. A review of the effects of moderate alcohol intake on the treatment of anxiety and mood disorders.
    Castaneda R, Sussman N, Westreich L, Levy R, O'Malley M.
    J Clin Psychiatry; 1996 May 15; 57(5):207-12. PubMed ID: 8626352
    [Abstract] [Full Text] [Related]

  • 13. Pathogenic involvement of neuropeptides in anxiety and depression.
    Alldredge B.
    Neuropeptides; 2010 Jun 15; 44(3):215-24. PubMed ID: 20096456
    [Abstract] [Full Text] [Related]

  • 14. Approaches to developing new anxiolytics and antidepressants.
    Dubovsky SL.
    J Clin Psychiatry; 1993 May 15; 54 Suppl():75-83. PubMed ID: 8099580
    [Abstract] [Full Text] [Related]

  • 15. The neurobiology of depression: inroads to treatment and new drug discovery.
    Nemeroff CB, Vale WW.
    J Clin Psychiatry; 2005 May 15; 66 Suppl 7():5-13. PubMed ID: 16124836
    [Abstract] [Full Text] [Related]

  • 16. sigma-1 receptors in major depression and anxiety.
    Kulkarni SK, Dhir A.
    Expert Rev Neurother; 2009 Jul 15; 9(7):1021-34. PubMed ID: 19589051
    [Abstract] [Full Text] [Related]

  • 17. Role of neuropeptides in anxiety, stress, and depression: from animals to humans.
    Kormos V, Gaszner B.
    Neuropeptides; 2013 Dec 15; 47(6):401-19. PubMed ID: 24210138
    [Abstract] [Full Text] [Related]

  • 18. [Domino principle--monoamines in bottom-view].
    Sümegi A.
    Neuropsychopharmacol Hung; 2008 Jun 15; 10(3):131-40. PubMed ID: 18956617
    [Abstract] [Full Text] [Related]

  • 19. 5-HT2 ligands in the treatment of anxiety and depression.
    Quesseveur G, Nguyen HT, Gardier AM, Guiard BP.
    Expert Opin Investig Drugs; 2012 Nov 15; 21(11):1701-25. PubMed ID: 22917059
    [Abstract] [Full Text] [Related]

  • 20. Anxiety disorders in the 21st century: status, challenges, opportunities, and comorbidity with depression.
    Devane CL, Chiao E, Franklin M, Kruep EJ.
    Am J Manag Care; 2005 Oct 15; 11(12 Suppl):S344-53. PubMed ID: 16236016
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.